Bristol-Myers Squibb share price logo

Bristol-Myers Squibb

NYSE: BMY

Large Cap

$63.06

+0.22

(+0.35%)

as on

Bristol-Myers Squibb Stock Performance

as on September 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $62.20
    $62.96
    downward going graph

    1.36%

    Downside

    -0.16%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $42.52
    $68.64
    downward going graph

    32.57%

    Downside

    8.85%

    Upside

    downward going graph

Bristol-Myers Squibb share price movements today

Previous Close
$62.84
Open
$62.66
Volume
6.9M
Market Cap
$130.2B
Dividend Yield
3.95%
Day's Low - High
$62.20 - $62.96
52 Week Low - High
$42.52 - $68.64

Bristol-Myers Squibb Historical Returns

1 Month Return
-7.06 %
3 Month Return
+ 16.37 %
1 Year Return
+ 39.58 %
3 Year Return
+ 7.18 %
5 Year Return
+ 2.5 %

Bristol-Myers Squibb Stock Fundamentals & Key Indicators

Check Bristol-Myers Squibb market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$130.2B

EPS (TTM)

4.54

Dividend Yield

3.95%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

13.84

Industry PE ratio

9.58

PEG Ratio

0.16812248844955419

EBITDA

16.7B

Revenue (TTM)

49.2B

Profit Margin

70.16%

Return On Equity TTM

46.75%

Bristol-Myers Squibb Stock Valuation

Track how Bristol-Myers Squibb P/E has moved over time to understand its valuation trends.

Bristol-Myers Squibb in the last 5 years

  • Overview

  • Trends

Lowest (-12.81x)

December 31, 2024

Industry (9.58x)

December 31, 2025

Today (15.59x)

December 31, 2025

Highest (24.22x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 15.59x

Bristol-Myers Squibb vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Bristol-Myers Squibb with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Bristol-Myers Squibb image
Bristol-Myers Squibb
HOLD$130.2B2.5%13.8470.16%3.95%
Eli Lilly & Co image
Eli Lilly & Co
BUY$1.1T400.84%38.5583.40%0.59%
AbbVie image
AbbVie
BUY$464.8B145.08%74.171.48%2.60%
Johnson & Johnson image
Johnson & Johnson
BUY$643.9B64.02%31.2467.91%1.98%
Merck & Company image
Merck & Company
BUY$354.8B105.29%115.014.77%2.35%
See all

Stock Returns calculator for Bristol-Myers Squibb Stock including INR - Dollar returns

The Bristol-Myers Squibb stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Bristol-Myers Squibb investment value today

Current value as on today

₹1,52,441

Returns

₹52,441

(+52.44%)

Returns from Bristol-Myers Squibb Stock

₹40,071 (+40.07%)

Dollar Impact

₹12,370 (+12.37%)

Analyst Recommendation on Bristol-Myers Squibb Stock

Based on 20 analysts

HOLD

40.00%

Buy

55.00%

Hold

5.00%

Sell

Based on 20 analysts, 55.00000000000001% of analysts recommend a 'HOLD' rating for Bristol-Myers Squibb. Average target price of $66.71

Bristol-Myers Squibb Share Price Target

Get share price movements and forecasts by analysts on Bristol-Myers Squibb.

What analysts predicted

5.47%UPSIDE

Target Price

$66.71

Current Price

$63.06

Analyzed by

20 Analysts

Target

$66.71

Bristol-Myers Squibb target price $66.71, a slight upside of 5.47% compared to current price of $63.06. According to 20 analysts rating.

Indian Investors' Interest in Bristol-Myers Squibb Stock

Search interest for Bristol-Myers Squibb Stock has decreased by -46% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-46% versus previous 30 day period

Bristol-Myers Squibb Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
11,865
12,201
11,892
12,342
11,201
12,269
12,222
12,503
11,489
12,973
Gross Profit
6,590
6,801
6,617
7,424
8,168
8,897
8,787
8,406
8,068
9,247
Operating Income
1,535
2,584
2,288
2,531
3,497
3,774
3,639
2,813
3,365
4,086
EBITDA
-8,559
4,403
4,773
2,551
4,477
3,269
4,605
2,879
4,245
4,940
Interest Expense
425
521
505
496
494
485
480
432
411
407
Depreciation
2,532
2,596
2,592
1,880
1,012
1,011
1,011
977
594
450
Income Before Tax
-11,516
1,286
1,676
175
2,971
1,773
3,114
1,470
3,240
4,086
Income Tax Expense
392
-398
461
99
509
460
919
384
561
770
Net Income
-11,911
1,680
1,211
72
2,456
1,310
2,201
1,087
2,677
3,317
Net Profit Margin
55.54%
55.74%
55.64%
60.15%
72.92%
72.52%
71.89%
67.23%
70.22%
71.28%

Bristol-Myers Squibb Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20,776
22,561
26,145
42,518
46,385
46,159
45,006
48,300
48,195
Gross Profit
14,958
16,075
17,250
21,700
26,761
26,490
25,357
27,432
34,259
Operating Income
5,239
6,394
6,439
4,492
9,540
9,271
8,472
9,658
13,724
EBITDA
6,116
6,788
7,377
4,929
20,118
19,221
19,366
3,168
15,230
Interest Expense
196
183
656
1,420
1,334
1,232
1,166
1,947
1,891
Depreciation
789
637
1,746
10,380
10,686
10,276
9,760
9,600
4,011
Income Before Tax
5,131
5,968
4,975
-6,871
8,098
7,713
8,440
-8,379
9,328
Income Tax Expense
4,156
1,021
1,515
2,124
1,084
1,368
400
554
2,272
Net Income
1,007
4,920
3,439
-8,995
6,994
6,327
8,025
-8,948
7,054
Net Profit Margin
72.00%
71.25%
65.98%
51.04%
57.69%
57.39%
56.34%
56.80%
71.08%

Bristol-Myers Squibb Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-11,908
1,684
1,215
76
2,462
1,313
2,195
1,085
2,678
3,316
Operating Cash Flow
2,834
2,326
5,591
4,439
1,954
3,917
6,311
1,974
1,104
3,393
Investing Cash Flow
-19,618
-1,319
-219
-196
-499
-473
-1,702
-1,458
-131
-1,614
Financing Cash Flow
14,644
-4,023
-3,852
-1,642
-993
-1,836
-1,490
-6,029
-1,560
-2,630
Change in Cash
-2,185
-3,038
1,597
2,454
528
1,736
3,115
-5,508
-635
-861

Bristol-Myers Squibb Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
975
4,947
3,460
-8,995
7,014
6,345
8,040
-8,933
7,055
Operating Cash Flow
5,275
7,066
8,210
14,052
16,207
13,066
13,860
15,190
14,156
Investing Cash Flow
-66
-2,000
-9,913
-10,859
-538
-1,062
-2,295
-21,352
-4,132
Financing Cash Flow
-4,077
-3,535
7,621
-1,151
-16,224
-16,962
-9,416
5,127
-10,348
Change in Cash
1,184
1,490
5,909
2,153
-657
-4,991
2,194
-1,172
-137

Mutual Funds that own Bristol-Myers Squibb Stock

Check out the Mutual Funds with significant holdings in Bristol-Myers Squibb.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
6.738976%
137658066
Fidelity Concord Street Trust
1.695335%
34630865
JPMorgan Trust II
0.803454%
16412278
VANGUARD CHESTER FUNDS
0.699728%
14293460
VANGUARD INSTITUTIONAL INDEX FUNDS
0.610126%
12463142
See all

Global Institutional Holdings in Bristol-Myers Squibb

Funds
Holdings
Vanguard
8.38%
iShares
5.09%
SPDR
4.07%
Schwab
3.13%
Theofanis Kolokotrones
1.22%
See all

Bristol-Myers Squibb News & Key Events

  • img

    Today's Timeline - 10 September

    Thu, 03:56 PM

    -

    HSBC raises BMY price target to $65 from $60, maintaining a Hold rating.

    Thu, 10:00 PM

    -

    BMY completes long-term psoriasis study, providing data on deucravacitinib's safety and efficacy.

    Thu, 10:00 PM

    -

    BMY backs Phase 3 trial comparing chemotherapy with nivolumab for bladder cancer treatment.

  • img

    Today's Timeline - 10 September

    Thu, 10:01 PM

    -

    BMY updates on ozanimod study against fingolimod for pediatric MS, aiming to expand market reach.

    Fri, 03:15 AM

    -

    Bristol Myers Squibb (BMY) declines 1.02%, underperforming the market; upcoming earnings forecast shows positive EPS and revenue growth.

Insights on Bristol-Myers Squibb

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Bristol-Myers Squibb Co. has shown positive revenue growth over the last two quarters. In the most recent quarter, the company's revenue increased from $11.48 billion to $12.97 billion, which represents an average growth of 11.4% per quarter.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Bristol-Myers Squibb Co. has shown strong financial performance in its net profit over the last three quarters. The company's net profit has increased from $1.08 billion to $3.31 billion, reflecting an average growth of 39.3% each quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, BMY stock has moved up by 16.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 36.8% return, outperforming this stock by 29.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Merck & Co., Inc. has given 80.2% return, outperforming this stock by 40.1%

About Bristol-Myers Squibb

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
OrganisationBristol-Myers Squibb
HeadquartersRoute 206 & Province Line Road, Princeton, NJ, 08543, US
IndustryDrug Manufacturers - General
CEOChristopher Boerner
E-voting on sharesClick here to vote

Key Management of Bristol-Myers Squibb

Name

Title

Dr. Christopher S. Boerner Ph.D.

CEO & Chairman

Mr. David V. Elkins

Executive VP & CFO

Mr. Greg Meyers

Executive VP and Chief Digital & Technology Officer

Mr. Cristian Massacesi M.D.

Executive VP, Chief Medical Officer & Head of Development

Ms. Karin Shanahan

Executive VP, Chief Supply Chain & Operations Officer

Ms. Cari Gallman

Executive VP, General Counsel & Chief Policy Officer

Dr. Joseph J. Eiden Jr.

Head of Medical Affairs

Mr. Adam Lenkowsky

Executive VP & Chief Commercialization Officer

Mr. Charles E. Triano

SVP & Head of Investor Relations

Ms. Ahn Amanda Poole

Executive VP & Chief People Officer

FAQs

What is Bristol-Myers Squibb share price today?

Bristol-Myers Squibb share price today is $63.06 as on at the close of the market. Bristol-Myers Squibb share today touched a day high of $62.96 and a low of $62.20.

What is the 52 week high and 52 week low for Bristol-Myers Squibb share?

Bristol-Myers Squibb share touched a 52 week high of $68.64 on and a 52 week low of $42.52 on . Bristol-Myers Squibb stock price today i.e. is closed at $63.06,which is 8.13% down from its 52 week high and 48.31% up from its 52 week low.

What is Bristol-Myers Squibb's market capitalisation today?

Bristol-Myers Squibb market capitalisation is $0.13T as on .

How to invest in Bristol-Myers Squibb Stock (BMY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Bristol-Myers Squibb on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Bristol-Myers Squibb Shares that will get you 0.0238 shares as per Bristol-Myers Squibb share price of $63.06 per share as on September 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Bristol-Myers Squibb Stock (BMY) from India?

Indian investors can start investing in Bristol-Myers Squibb (BMY) shares with as little as ₹95.88 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.80 in Bristol-Myers Squibb stock (as per the Rupee-Dollar exchange rate as on ). Based on Bristol-Myers Squibb share’s latest price of $63.06 as on September 19, 2026 at 8:45 am IST, you will get 0.1586 shares of Bristol-Myers Squibb. Learn more about fractional shares .

What are the returns that Bristol-Myers Squibb has given to Indian investors in the last 5 years?

Bristol-Myers Squibb stock has given 2.5% share price returns and 30.29% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?